Sol Gel Technologies Ltd
NASDAQ:SLGL
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
4.1
72.1
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| IL |
|
Sol Gel Technologies Ltd
NASDAQ:SLGL
|
200.9m USD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
984.9B USD |
Loading...
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
525.1B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
273.3B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
207.6B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
218.5B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
272.2B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.7T DKK |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
145.1B USD |
Loading...
|
Market Distribution
| Min | -84 760% |
| 30th Percentile | -5.8% |
| Median | 4% |
| 70th Percentile | 10.9% |
| Max | 23 869.1% |
Other Profitability Ratios
Sol Gel Technologies Ltd
Glance View
Sol-Gel Technologies Ltd. is a clinical-stage dermatology company, which engages in the identification, development, and commercialization of topical dermatological drug products for the treatment of skin diseases. The firm is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The firm is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Sol Gel Technologies Ltd is -53.9%, which is above its 3-year median of -801.4%.
Over the last 3 years, Sol Gel Technologies Ltd’s Operating Margin has decreased from 15.9% to -53.9%. During this period, it reached a low of -2 502.7% on Sep 30, 2023 and a high of 15.9% on Aug 30, 2022.